Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services.
Injection drug use (IDU) plays a critical role in the HIV epidemic in several countries throughout the world. In these countries, injection drug users are at significant risk for both HIV and tuberculosis, and active IDU negatively impacts treatment access, adherence and retention. Comprehensive strategies are therefore needed to effectively deliver preventive, diagnostic and curative services to these complex patient populations. We propose that developing co-located integrated care delivery systems should become the focus of national programmes as they continue to scale-up access to antiretroviral medications for drug users. Existing data suggest that such a programme will expand services for each of these diseases; increase detection of tuberculosis (TB) and HIV; improve medication adherence; increase entry into substance use treatment; decrease the likelihood of adverse drug events; and improve the effectiveness of prevention interventions. Key aspects of integration programmes include: co-location of services convenient to the patient; provision of effective substance use treatment, including pharmacotherapies; cross-training of generalist and specialist care providers; and provision of enhanced monitoring of drug-drug interactions and adverse side effects. Central to implementing this agenda will be fostering the political will to fund infrastructure and service delivery, expanding street-level outreach to IDUs, and training community health workers capable of cost effectively delivering these services.
Sylla
Laurie
L
Yale University AIDS Programme, 135 College Street, Suite 323, New Haven, CT 06510, United States.
Bruce
R Douglas
RD
Kamarulzaman
Adeeba
A
Altice
Frederick L
FL
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000517:prevention & control / Q000523:psychology; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control / Q000523:psychology; D006801:Humans; D011314:Preventive Health Services / Q000458:organization & administration*; D011320:Primary Health Care / Q000379:methods*; D016730:Program Development; D019966:Substance-Related Disorders / Q000188:drug therapy / Q000517:prevention & control / Q000523:psychology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000517:prevention & control / Q000523:psychology; D035862:Vulnerable Populations
D044966:Anti-Retroviral Agents; D000995:Antitubercular Agents
J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):251-9
11464144
Int J Drug Policy. 2007 Aug;18(4):326-8
17689382
J Clin Virol. 2001 Oct;22(3):279-87
11564593
J Acquir Immune Defic Syndr. 2001 Sep 1;28(1):28-34
11579274
Soc Sci Med. 2002 Jul;55(2):235-46
12144138
Public Health Nurs. 2002 Sep-Oct;19(5):345-53
12182694
Arch Intern Med. 2003 May 12;163(9):1009-21
12742798
J Urban Health. 2003 Sep;80(3):416-27
12930880
Health Policy. 2003 Sep;65(3):227-41
12941491
AIDS Read. 2003 Aug;13(8):378-9
14524323
Drug Alcohol Depend. 2003 Oct 24;72(1):13-21
14563539
Wien Klin Wochenschr. 2003 Oct 31;115(19-20):685-97
14650943
J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):46-51
14707791
Ann Pharmacother. 2004 Apr;38(4):550-6
14990778
AIDS. 2004 Apr 30;18(7):975-9
15096799
Trop Med Int Health. 2004 Jun;9(6):A11-5
15189469
AIDS Care. 2004 May;16(4):485-500
15203416
AIDS Educ Prev. 2004 Jun;16(3 Suppl A):155-69
15262573
Int J Tuberc Lung Dis. 2004 Aug;8(8):988-93
15305482
Hopkins HIV Rep. 2004 Jul;16(4):5-7
15386835
Am J Respir Crit Care Med. 1998 Jul;158(1):157-61
9655723
JAMA. 1998 Aug 12;280(6):544-6
9707145
JAMA. 1998 Aug 12;280(6):547-9
9707146
J Public Health Manag Pract. 1995 Fall;1(4):40-7
10186640
Antimicrob Agents Chemother. 1998 Dec;42(12):3107-12
9835499
Int J Tuberc Lung Dis. 1999 Feb;3(2):153-5
10091882
Am J Respir Crit Care Med. 1999 Jul;160(1):178-85
10390397
East Mediterr Health J. 2002 Nov;8(6):754-7
15568452
AIDS. 2004 Nov 19;18(17):2295-303
15577542
Addiction. 2005 Feb;100(2):150-8
15679744
N Engl J Med. 2005 Feb 10;352(6):586-95
15703423
Am J Med. 2005 Mar;118(3):292-300
15745728
AIDS. 2005 Mar 4;19(4):441-3
15750399
J Urban Health. 2005 Mar;82(1):151-61
15746385
Int J STD AIDS. 2005 Feb;16(2):95-100; quiz 101
15807935
Indian J Med Res. 2005 Apr;121(4):550-67
15817963
AIDS Patient Care STDS. 2005 May;19(5):298-305
15916492
Am J Prev Med. 2005 Jul;29(1):27-33
15958248
J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):464-70
16010171
Clin Infect Dis. 2005 Sep 15;41(6):891-6
16107991
Nat Rev Immunol. 2005 Oct;5(10):819-26
16200083
Clin Infect Dis. 2006 Mar 1;42(5):716-21
16447120
BMC Public Health. 2005;5:130
16343345
Int J STD AIDS. 2006 May;17(5):354-5
16643689
J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):563-72
16652030
AIDS Behav. 2006 May;10(3):287-97
16485072
AIDS. 2006 Jun 12;20(9):1349-51
16816575
Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S178-83
17109304
Int J Tuberc Lung Dis. 2006 Nov;10(11):1224-30
17131780
J Acquir Immune Defic Syndr. 2006 Dec 1;43 Suppl 1:S48-53
17133204
AIDS. 2001 Sep 7;15(13):1707-15
11546947